Every Form 4 that Forte Biosciences Inc (FBRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBRX filings page.
Forte Biosciences, Inc. (FBRX) director Steven Kornfeld reported that, in connection with a merger in which Forte became a wholly owned subsidiary of argenx BV, all of his reported Forte equity was disposed of on August 27, 2026. Common shares that were tendered were exchanged for $77.00 per share in cash, net to the seller, subject to withholding tax.
Unexercised stock options with exercise prices below $77.00 were canceled and converted into the right to receive a lump-sum cash payment equal to the excess of the $77.00 Merger Consideration over the option’s exercise price, multiplied by the number of shares subject to each option. Options with exercise prices at or above $77.00 were canceled with no consideration. All reported restricted stock units were canceled and converted into the right to receive a cash payment equal to $77.00 multiplied by the number of underlying shares.
Forte Biosciences, Inc. (FBRX) director Scott C. Brun reported the cancellation and disposition to the issuer of stock options and restricted stock units in connection with a merger. On August 27, 2026, unexercised options with per share exercise prices below the $77.00 merger consideration and outstanding RSUs were canceled and converted into rights to receive lump-sum cash payments, while options with exercise prices at or above $77.00 were canceled for no consideration.
Forte Biosciences, Inc. (FBRX) director David W. Gryska reported dispositions of common stock and equity awards in connection with the company’s merger with argenx BV. He tendered 5,940 shares of common stock into a tender offer at $77.00 per share in cash. Unexercised stock options with exercise prices below $77.00 covering 36,000 shares in total and 18,353 restricted stock units were canceled and converted into lump-sum cash rights based on the $77.00 Merger Consideration, subject to withholding taxes, while certain higher-priced options were canceled with no consideration. Following the merger, Forte Biosciences became a wholly owned subsidiary of argenx BV.
Forte Biosciences, Inc. (FBRX) director Richard G. Vincent reported the disposition of equity awards in connection with a merger under which Forte becomes a wholly owned subsidiary of argenx BV. On 2026-08-27, unexercised stock options for 2,000 shares at a $7.07 exercise price and 31,000 shares at a $7.54 exercise price, and 18,353 restricted stock units, were canceled. Under the Merger Agreement, in-the-money options and RSUs are converted into a right to receive cash based on $77.00 per share, while options with exercise prices at or above that amount are canceled with no consideration.
Forte Biosciences, Inc. (FBRX) reported that director Barbara K. Finck disposed of multiple equity awards in connection with the closing of a merger under an Agreement and Plan of Merger. On August 27, 2026, several stock option grants and a block of restricted stock units were cancelled and converted, under the merger terms, into rights to receive cash based on a $77.00 per share Merger Consideration, while options with exercise prices at or above that amount were cancelled with no consideration.
Forte Biosciences, Inc. (FBRX) director Shivpreet Singh Kapoor reported the disposition of equity awards in connection with a merger under the July 26, 2026 Agreement and Plan of Merger among Forte, argenx BV and Avena Merger Sub Inc. Unexercised stock options with exercise prices below $77.00 per share and restricted stock units were canceled and converted into cash rights, while options with exercise prices at or above $77.00 were canceled for no consideration.
Forte Biosciences, Inc. (FBRX) reported that director Stephen K. Doberstein disposed of several equity awards in connection with a merger under an Agreement and Plan of Merger with argenx BV and Avena Merger Sub Inc. On 2026-08-27, multiple stock options and restricted stock units were cancelled and converted into cash rights pursuant to the merger terms.
Stock options with exercise prices below the $77.00 per share merger consideration, including grants for 2,000 shares at $29.50, 1,000 at $31.75, 1,000 at $20.00, 2,000 at $8.60, and 31,000 at $7.54, were cancelled and converted into a right to receive a lump-sum cash payment based on the excess of the merger consideration over the exercise price, multiplied by the shares subject to each option. Options with exercise prices at or above $77.00 per share were cancelled with no consideration.
In addition, 18,353 restricted stock units, each representing a contingent right to one share of common stock, were cancelled and converted into a lump-sum cash payment equal to the merger consideration multiplied by the number of underlying shares. The filing indicates these transactions were dispositions to the issuer rather than open-market trades, and the Rule 10b5-1 trading plan box was not checked.
Forte Biosciences, Inc. (FBRX) reported that its Chief Financial Officer, Antony A. Riley, disposed of all reported equity interests in connection with the completed acquisition of the company by argenx BV. On August 27, 2026, Riley tendered 42,600 shares of common stock in a transaction pursuant to a tender offer under a Merger Agreement, receiving $77.00 per share in cash, subject to withholding taxes. In-the-money Forte stock options and restricted stock units were canceled and converted into cash rights based on the same $77.00 Merger Consideration per underlying share, while options with exercise prices at or above that amount were canceled with no consideration.
Forte Biosciences, Inc. (FBRX) reports that CEO, Secretary and Chair Paul A. Wagner disposed of his equity interests in connection with the closing of a merger with argenx BV. On 2026-08-27, 85,482 shares of common stock were tendered and exchanged for $77.00 per share in cash under a tender offer, leaving no directly held common shares reported.
Pursuant to the merger agreement, multiple unexercised stock options with per-share exercise prices below $77.00 were canceled and converted into cash rights equal to the cash consideration minus the exercise price, multiplied by the number of option shares. Options with exercise prices at or above $77.00 were canceled with no payment. Outstanding restricted stock units were also canceled and converted into cash equal to $77.00 times the number of underlying shares.
Forte Biosciences, Inc. chief financial officer Riley Antony reported compensation-related stock activity. On July 1, 2026, he exercised 375 Restricted Stock Units (RSUs), receiving the same number of Common Stock shares. To cover tax obligations, 134 Common Stock shares were disposed of via share withholding, not an open-market sale.
Following these transactions, Antony holds 42,600 Common Stock shares directly, according to the filing, which includes 377 shares acquired under the 2017 Employee Stock Purchase Plan. The activity reflects routine RSU vesting and tax withholding rather than discretionary buying or selling in the market.
Forte Biosciences director and officer Paul A. Wagner reported routine equity compensation activity. On July 1, 2026, he exercised restricted stock units to acquire 1,250 shares of Common Stock at a conversion price of $0.00 per share.
To cover tax obligations, 98 shares of Common Stock were disposed of in a tax-withholding transaction at $21.32 per share, which is not an open-market sale. After these transactions, Wagner directly owned 85,482 shares of Common Stock and 2,500 Restricted Stock Units, each RSU representing a contingent right to receive one share, subject to continued service and quarterly vesting under the 2021 Equity Incentive Plan.
Forte Biosciences, Inc. reported that Chief Financial Officer Antony A. Riley received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036.
According to the disclosure, all 22,000 option shares were held directly after the transaction, reflecting a compensation-related award rather than an open-market purchase. The footnotes state that, subject to continued service, one forty-eighth of the options will vest monthly starting on the Vesting Commencement Date of June 16, 2026, so the grant is scheduled to be fully vested four years after that date.
Forte Biosciences director and officer Paul A. Wagner received a grant of stock options for 500,000 shares of Common Stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036. This is a compensation-related award, not an open-market purchase.
According to the vesting terms, beginning on the Vesting Commencement Date of June 16, 2026, one forty-eighth of the options vest each month, so the award becomes fully vested over four years if he continues as a service provider.
Doberstein Stephen K reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Stephen K. Doberstein received a grant of 18,353 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of Forte Biosciences common stock.
All 18,353 RSUs will vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, as long as Doberstein continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan through that date. After this award, he is reported as directly holding 18,353 RSUs.
Forte Biosciences director Shivpreet Singh Kapoor received a grant of 18,353 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Forte Biosciences, Inc. common stock. The award was granted at no exercise price as equity compensation.
All 18,353 RSUs will vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, provided Kapoor continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan through that date. Following this grant, Kapoor directly holds 18,353 RSUs tied to an equal number of underlying common shares.
VINCENT RICHARD G reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Richard G. Vincent received a grant of 18,353 restricted stock units (RSUs), each representing a contingent right to one share of common stock. All RSUs will vest in full at the first annual stockholder meeting occurring after May 29, 2026, if he continues as a service provider.
GRYSKA DAVID W reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director David W. Gryska received a grant of 18,353 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Forte Biosciences common stock.
The RSUs will fully vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, as long as Gryska continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan. Following this award, he directly holds 18,353 RSUs, with no open-market purchases or sales reported in this filing.
Brun Scott C. reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Scott C. Brun reported receiving a grant of 18,353 restricted stock units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of Forte common stock.
The award vests in full at the first annual stockholder meeting that occurs after May 29, 2026, as long as Brun continues serving as a “Service Provider” under the company’s 2021 Equity Incentive Plan through that date. Following this grant, he holds 18,353 RSUs directly, reflecting equity-based compensation rather than an open‑market purchase or sale.
Kornfeld Steven reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Steven Kornfeld received a grant of restricted stock units as equity compensation. He was awarded 18,353 RSUs, each representing one share of common stock at a price of $0.00 per unit. Following this award, he holds 18,353 RSUs directly.
According to the grant terms, 100% of these RSUs will vest on the date of the first annual stockholder meeting that occurs after May 29, 2026, provided he continues as a Service Provider under the company’s 2021 Equity Incentive Plan through that date.
Forte Biosciences, Inc. chief financial officer Antony A. Riley exercised restricted stock units that converted into 375 shares of Common Stock on April 1, 2026. These RSUs had a conversion price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.
To cover tax obligations from the vesting, 134 Common Shares were withheld at $24.86 per share, which is treated as a tax-withholding disposition rather than a traditional stock sale. After these transactions, Riley directly held 41,982 Common Shares and 1,125 RSUs, representing ongoing equity exposure to the company.
Forte Biosciences, Inc. director and officer Paul A. Wagner reported routine equity compensation activity. On April 1, 2026, 1,250 restricted stock units vested and were exercised into an equal number of common shares at a stated price of $0.00 per share.
To cover tax obligations on this vesting, 98 common shares were withheld at $24.86 per share, a non-market tax-withholding disposition rather than an open-market sale. After these transactions, Wagner directly holds 84,330 common shares and 3,750 RSUs, reflecting a net increase in his equity position.
The RSUs vest in installments, with one-sixteenth of the award vesting on each Quarterly Vesting Date—January 1, April 1, July 1, and October 1—under the company’s 2021 Equity Incentive Plan, so similar compensation-related transactions may continue as future tranches vest.
Forte Biosciences reported that its Chief Financial Officer, Riley Antony A, received new equity awards effective January 12, 2026. The awards include a stock option covering 90,000 shares of common stock with an exercise price of $29.66 per share and an expiration date of January 12, 2036, and a grant of 60,000 restricted stock units (RSUs).
The option vests monthly, with one forty-eighth of the total option shares vesting each month starting from a vesting commencement date of January 1, 2026, so that the option is fully vested after four years. The RSUs vest annually, with one fourth of the total RSUs vesting on each anniversary of the same January 1, 2026 vesting commencement date, resulting in full vesting over four years, assuming the CFO continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan.
Forte Biosciences, Inc. reported new equity awards to a senior executive. A Form 4 filing shows that on January 12, 2026, CEO, Secretary and Chair Paul A. Wagner received a stock option covering 270,000 shares of Forte Biosciences common stock with an exercise price of $29.66 per share. According to the vesting terms, one forty-eighth of the option vests each month after a vesting commencement date of January 1, 2026, so the option becomes fully vested after four years, as long as he continues as a service provider.
The filing also reports a grant of 180,000 restricted stock units, each representing a contingent right to receive one share of Forte Biosciences common stock. These RSUs vest in four equal annual installments on each anniversary of the same January 1, 2026 vesting commencement date, again conditioned on continued service. Following these grants, Wagner beneficially owns 270,000 stock options and 180,000 RSUs directly.
Riley Antony A reported disposition transactions in this Form 4 filing.
Forte Biosciences, Inc. chief financial officer Riley Antony A exercised 375 restricted stock units into an equal number of common shares on October 1, 2025. In connection with this vesting, 134 common shares were delivered at $14.52 per share to satisfy tax liability. Following these transactions, Antony directly holds 31,840 Forte Biosciences common shares and 1,875 RSUs remain outstanding under an award that vests one‑sixteenth on each quarterly vesting date, subject to continued service.
Paul A. Wagner, CEO, Secretary and Chair of Forte Biosciences, Inc. (FBRX), reported an award of 1,250 restricted stock units (RSUs) on 10/01/2025. Each RSU converts into one share of common stock at $0. The RSUs vest in 16 quarterly installments (one-sixteenth each) beginning on or immediately after February 1, 2023, subject to continued service under the 2021 Equity Incentive Plan. The report also shows a separate sale of 98 shares on 10/01/2025 at $14.52, leaving total beneficial ownership of 82,092 shares after the transactions.